Investing

JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%

Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.

adminadmin
May 22, 2024 - 00:00
 0  11
JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%
Structure Therapeutics could one day boast a competitive obesity product and go up against Eli Lilly and the like, according to JPMorgan.
Read More

Tags:

Previous Article

Morgan Stanley says shares of this Nvidia supplier could pop if AI leader gives ...

Next Article

JPMorgan strategist stays stubbornly negative on stocks even as other Wall Stree...

admin
admin

Related Posts

Nvidia is missing key technology and could acquire these stocks to get it, says Susquehanna analyst

Nvidia is missing key technology and could acquire thes...

admin Sep 27, 2024  0  65

Bank of America likes these solid dividend-paying stocks for August

Bank of America likes these solid dividend-paying stock...

admin Aug 22, 2024  0  5

These 'Trump trades' are on a roll and analysts see more gains ahead

These 'Trump trades' are on a roll and analysts see mor...

admin Nov 10, 2024  0  6